Loading...

NUVB NUVATION BIO INC Business Restructuring 8-K Filing

NVTN

NVB

NUVATION BIO INC

(NUVB)

2025 8-K

Annual Meeting Results

Financial Results Announced

Financial Results Announced

New License Agreement

Drug Development Update

Positive Study Results

Financial Results Released

Earnings Releases

Pre-Market Approval

Financial Statements

Supply Agreement

Financial Results

Supply Agreement

Loan Agreements

Financial Results

CFO Appointment

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

Acquisition Completed

Merger Agreement

Financial Results Announcement

Appointment of Director

Resignation of Director

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Earnings Reports

Petition for Resolution of ...

External Links:

On November 26, 2025, Nuvation Bio Inc. announced it would discontinue development of NUV-1511 due to inconsistent efficacy, reallocating the estimated $100-150 million for R&D to other projects. The company remains committed to its drug-drug conjugate platform and ongoing studies like G203 and the commercial launch of IBTROZI.

AI Assistant

NUVATION BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.